Specialization
Brachytherapy, Urological tumors, Gyneacological Brachytherapy
Focus of research
Bradley Pieters was trained as radiation oncologist at the Catholic University Nijmegen (presently Radboud University). The training for radiation oncologist was finalized in 1995. During his training he did a 5 month fellowship on brachytherapy at the Daniel den Hoed Kliniek in Rotterdam and L'Institut Gustave-Roussy in Villejuif. He finalized his training and specialisation in brachytherapy at the Academic Medical Center in Amsterdam. He is by now recognized as a leader in the field of brachytherapy and was Chair of GEC-ESTRO (Group Européen de Curiethérapie-European Society for Radiotherapy and Oncology).
In 2006 he obtained his Master of Science in clinical epidemiology at the Institute for Research in Extramural Medicine of the Free University Medical Center of Amsterdam. After graduating for PhD he was registered as Post-doctoral Medical-Biological Research Epidemiologist at the National Committee for Medical-Biological Research Training in the Netherlands (SMBWO).
In 2010 he obtained his PhD after defending the thesis 'Pulsed-dose rate brachytherapy in prostate cancer' under supervisorship of Prof. dr. C. Koning (promotor).
Field of research
Dr. Bradley Pieters field of work is mainly general brachytherapy with special dedication for prostate malignancies, gynecologic malignancies, pediatric malignacies, and bladder malignancies. He is head of the department of Brachytherapy at the Amsterdam University Medical Centers. Different types of isotopes and brachytherapy techniques are used at the AMC such as Sr-90, I-125, PDR and HDR brachytherapy.
Clinical research on brachytherapy and translational research for advanced and automatic treatment planning in the field of brachytherapy
The focus of research is in developing brachytherapy by paying attention to toxicity and developing new techniques to limit it. Ways to achieve this is by designing new therapies and by improving treatment planning, for example with automated AI-based technology.
Clinical studies
* Randomized Phase 3 Study On The Assessment Of Late Toxicity By Comparing IMRT High Dose External Beam Radiotherapy Only With External Beam Radiotherapy Combined With HDR Or PDR Brachytherapy In Patients With Intermediate/high Risk Prostate Cancer PROBACH trial (NTR3897),
* Which correction protocol gives the lowest cumulative rectal dose in prostate cancer patients who are treated with external beam radiotherapy? A phase II Modelling study (NTR 879),
* Contrast enhanced ultrasound imaging to support prostate cancer brachytherapy treatment and follow up after treatment (NTR 1168),
* POWER trial (NL7073) Randomized trial for the evaluation of erectile dysfunction after whole or partial gland prostate brachytherapy,
* Fast, accurate, and insightful brachytherapy treatment planning for cervical cancer through artificial intelligence (KWF 12183).
*3D study growth disruption after rhabdomyosarcoma treatment (Prof. dr. L. Smeele and Prof. dr. A. Becking).